Diabetic Dyslipidaemia

Overview

Journal Pract Lab Med

Specialty Biochemistry

Date 2021 Aug 9

PMID 34368411

Citations 9

Authors

Subashini C Thambiah

Leslie Charles Lai

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus (DM) is an escalating pandemic and an established cardiovascular risk factor. An important aspect of the interaction between DM and atherosclerotic cardiovascular disease (ASCVD) is diabetic dyslipidaemia, an atherogenic dyslipidaemia encompassing quantitative [hypertriglyceridaemia (hyperTG) and decreased high density lipoprotein cholesterol (HDL)] and qualitative [increased small dense low density lipoprotein cholesterol (sdLDL) particles, large very low density lipoprotein cholesterol (VLDL) subfraction (VLDL1) and dysfunctional HDL] modifications in lipoproteins. Much of the pathophysiology linking DM and dyslipidaemia has been elucidated. This paper aims to review the pathophysiology and management of diabetic dyslipidaemia with respect to ASCVD. Briefly, the influence of diabetic kidney disease on lipid profile and lipid changes causing type 2 diabetes mellitus are highlighted. Biomarkers of diabetic dyslipidaemia, including novel markers and clinical trials that have demonstrated that non-lipid and lipid lowering therapies can lower cardiovascular risk in diabetics are discussed. The stands of various international guidelines on lipid management in DM are emphasised. It is important to understand the underlying mechanisms of diabetic dyslipidaemia in order to develop new therapeutic strategies against dyslipidaemia and diabetes. The various international guidelines on lipid management can be used to tailor a holistic approach specific to each patient with diabetic dyslipidaemia.

Citing Articles

Fermented Larvae Alleviates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in C57BL/6 Mice via Regulation of Lipid Accumulation and Inflammation.

Lee H, Kim J, Go M, Lee H, Kim J, Kim I J Microbiol Biotechnol. 2025; 35:e2409025.

PMID: 39947694 PMC: 11876019. DOI: 10.4014/jmb.2409.09025.

Glycemic Control and Cardiometabolic Risk in Black Zimbabweans with Type 2 Diabetes Mellitus.

Chiveto D, Musarurwa C, Mapira H, Kaseke F, Nyengerai T, Kaseke T Diabetes Metab Syndr Obes. 2024; 17:3187-3196.

PMID: 39220799 PMC: 11365488. DOI: 10.2147/DMSO.S473042.

Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry.

Shiyovich A, Berman A, Besser S, Biery D, Cardoso R, Divakaran S Cardiovasc Diabetol. 2024; 23(1):257.

PMID: 39026226 PMC: 11264681. DOI: 10.1186/s12933-024-02348-2.

Associations between Serum Kallistatin Levels and Markers of Glucose Homeostasis, Inflammation, and Lipoprotein Metabolism in Patients with Type 2 Diabetes and Nondiabetic Obesity.

Lorincz H, Csiha S, Ratku B, Somodi S, Sztanek F, Paragh G Int J Mol Sci. 2024; 25(11).

PMID: 38892451 PMC: 11173135. DOI: 10.3390/ijms25116264.

In-lab synthesized turn-off fluorescence sensor for estimation of Gemigliptin and Rosuvastatin polypill appraised by Spider diagram, AGREE and whiteness metrics.

Mohyeldin S, Talaat W, Kamal M, Daabees H, El-Tahawy M, Keshk R Sci Rep. 2024; 14(1):2927.

PMID: 38316908 PMC: 10844310. DOI: 10.1038/s41598-024-53203-z.

References

Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y . Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2009; 206(2):535-9. DOI: 10.1016/j.atherosclerosis.2009.03.029. View

Thambiah C, Mohamed Pesri N, Mazalan N, Samsudin I, Mohamad Ismuddin S, Appannah G . A pilot study on pattern B lipoprotein profile in Malaysia. Malays J Pathol. 2020; 42(2):215-225. View

Goldberg I . Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001; 86(3):965-71. DOI: 10.1210/jcem.86.3.7304. View

Jialal I, Singh G . Management of diabetic dyslipidemia: An update. World J Diabetes. 2019; 10(5):280-290. PMC: 6522756. DOI: 10.4239/wjd.v10.i5.280. View

Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3):203-12. DOI: 10.1056/NEJMoa1300955. View

Cai R, Yuan Y, Zhou Y, Xia W, Wang P, Sun H . Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. PLoS One. 2014; 9(8):e104922. PMC: 4133238. DOI: 10.1371/journal.pone.0104922. View

Saha S, Kizhakepunnur L, Bahekar A, Arora R . The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007; 154(5):943-53. DOI: 10.1016/j.ahj.2007.07.011. View

Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T . Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. Cardiovasc Drugs Ther. 2018; 32(1):73-80. PMC: 5843683. DOI: 10.1007/s10557-018-6776-z. View

Filippatos T, Tsimihodimos V, Pappa E, Elisaf M . Pathophysiology of Diabetic Dyslipidaemia. Curr Vasc Pharmacol. 2017; 15(6):566-575. DOI: 10.2174/1570161115666170201105425. View

10.

Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A . Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307(23):2499-506. PMC: 4211641. DOI: 10.1001/jama.2012.6571. View

11.

Mora S, Kamstrup P, Rifai N, Nordestgaard B, Buring J, Ridker P . Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010; 56(8):1252-60. PMC: 2912456. DOI: 10.1373/clinchem.2010.146779. View

12.

Monami M, Sesti G, Mannucci E . PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab. 2018; 21(4):903-908. DOI: 10.1111/dom.13599. View

13.

. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995; 75(14):894-903. DOI: 10.1016/s0002-9149(99)80683-3. View

14.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

15.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

16.

Virani S . Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011; 38(2):160-2. PMC: 3066801. View

17.

Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls S . Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375(9729):1875-84. DOI: 10.1016/S0140-6736(10)60656-3. View

18.

. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016; 39(5):686-93. PMC: 4839174. DOI: 10.2337/dc15-1990. View

19.

Chillaron J, Flores Le-Roux J, Benaiges D, Pedro-Botet J . Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2013; 63(2):181-7. DOI: 10.1016/j.metabol.2013.10.002. View

20.

Summerhill V, Grechko A, Yet S, Sobenin I, Orekhov A . The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int J Mol Sci. 2019; 20(14). PMC: 6678182. DOI: 10.3390/ijms20143561. View